Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 216, Issue 4, Pages 436-446Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jix291
Keywords
immune metabolism; fetal development; HIV-1; metabolomics; antiretroviral therapy
Categories
Funding
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)-Zon Mw [435002027]
- Virgo consortium
- Dutch government [FES0908]
- Netherlands Organisation for Scientific Research Agiko Stipendium [92003417]
- Dutch AIDS Foundation [2006015]
Ask authors/readers for more resources
Increased morbidity and fetal growth restriction are reported in uninfected children born to human immunodeficiency virus type 1 (HIV-1)-infected women treated with antiretroviral (ARV) therapy. Viruses and/or pharmacological interventions such as ARVs can induce metabolic stress, skewing the cell's immune response and restricting (cell) growth. Novel metabolomic techniques provided the opportunity to investigate the impact of fetal HIV-1 and combination ARV therapy (cART) exposure on the infants' immune metabolome. Peroxidized lipids, generated by reactive oxygen species, were increased in cART/HIV-1-exposed infants, indicating altered mitochondrial functioning. The lipid metabolism was further dysregulated with increased triglyceride species and a subsequent decrease in phospholipids in cART/HIV-1-exposed infants compared to control infants. Proinflammatory immune mediators, lysophospholipids as well as cytokines such as CXCL10 and CCL3, were increased whereas anti-inflammatory metabolites from the cytochrome P450 pathway were reduced in cART/HIV-1-exposed infants. Taken together, these data demonstrate that the fetal metabolism is impacted by maternal factors (cART and HIV-1) and skews physiological immune responses toward inflammation in the newborn infant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available